This inventor holds 3 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 3 EPO patents. Top assignee: Chong Kun Dang Pharmaceutical Corporation. Active years: 2020-2026.
Company Filing History:
Years Active: 2020-2026
Title: Moo Sung Ko: Innovator in Pharmaceutical Compounds
Introduction
Moo Sung Ko is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit histone deacetylase 6 (HDAC6). With a total of 3 patents to his name, his work is paving the way for new therapeutic options.
Latest Patents
Moo Sung Ko's latest patents focus on 1,3,4-oxadiazole derivative compounds that serve as HDAC6 inhibitors. These novel compounds exhibit HDAC6 inhibitory activity, which is crucial for the prevention and treatment of various diseases, including cancer, inflammatory diseases, autoimmune diseases, and neurological or neurodegenerative diseases. The patents detail the use of these compounds in preparing therapeutic medicaments, as well as the pharmaceutical compositions that contain them.
Career Highlights
Moo Sung Ko is currently associated with Chong Kun Dang Pharmaceutical Corporation, where he continues to innovate in the pharmaceutical sector. His expertise in developing compounds with therapeutic potential has established him as a key figure in his field.
Collaborations
Moo Sung Ko collaborates with notable colleagues, including Seok Hyoun Yun and Chang Kon Lee. Their combined efforts contribute to advancing research and development in pharmaceutical sciences.
Conclusion
Moo Sung Ko's work in developing HDAC6 inhibitors represents a significant advancement in the treatment of various diseases. His contributions to the pharmaceutical industry are noteworthy and continue to impact the field positively.